Evaluation Study of SPOTme® Skin Cancer Screenings

NCT ID: NCT03564769

Last Updated: 2019-08-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

431 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-12-01

Study Completion Date

2019-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the impact of the AAD SPOTme® skin cancer screening events on attendees' skin cancer prevention and detection behaviors. This study will also evaluate whether an educational intervention will improve post-screening engagement of attendees with dermatologists.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Despite tremendous growth in both the interest and volume of skin cancer screenings at the national level, the actual utility and impact of the AAD SPOT me™ skin cancer screening programs have not been fully evaluated. This study will address this knowledge gap. Early detection is vital in the fight against skin cancer, the most common cancer in the United States. While the effects of skin cancer can be devastating, this disease is highly treatable when detected early.

This study evaluates the impact of the AAD SPOTme® skin cancer screening events on attendees' skin cancer prevention and detection behaviors. This study will also evaluate whether an educational intervention will improve post-screening engagement of attendees with dermatologists.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Arm 1

Individuals randomized to intervention group 1 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 AND will receive additional skin cancer screening educational materials.

Group Type EXPERIMENTAL

Intervention Arm

Intervention Type BEHAVIORAL

Individuals randomized to the intervention group will receive skin cancer screening educational materials.

AAD SPOTmeⓇ skin cancer screening

Intervention Type OTHER

All study participants will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017.

Intervention Arm 2

Individuals randomized to intervention group 2 will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017 only.

Group Type EXPERIMENTAL

AAD SPOTmeⓇ skin cancer screening

Intervention Type OTHER

All study participants will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intervention Arm

Individuals randomized to the intervention group will receive skin cancer screening educational materials.

Intervention Type BEHAVIORAL

AAD SPOTmeⓇ skin cancer screening

All study participants will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participated in the American Academy of Dermatology national screening program in 2016 or 2017
* Have a presumptive diagnosis (screening, non-confirmed) of melanoma
* Have provided the AAD with permission to be re-contacted
* Have provided the AAD with an email address
* Aged 18 years or older
* Able to read English

Exclusion Criteria

* None
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

American Academy of Dermatology (AAD)

UNKNOWN

Sponsor Role collaborator

Harvard School of Public Health (HSPH)

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alan Geller

MPH, RN

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alan Geller, MPH, RN

Role: PRINCIPAL_INVESTIGATOR

Harvard TH Chan School of Public Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Harvard TH Chan School of Public Health

Boston, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

17-1668

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Healthy Corner Store Initiative
NCT00593749 COMPLETED NA
I-ACT With Check Yourself
NCT02764190 COMPLETED NA
MyHeart Counts Cardiovascular Health Study
NCT03090321 ACTIVE_NOT_RECRUITING NA
Family Check-Up Online
NCT06161597 ACTIVE_NOT_RECRUITING NA